Publications by authors named "S L Wanders"
Article Synopsis
- This study addresses the lack of guidelines for biologic dose reduction in psoriasis treatment, aiming for clear criteria to support consistent practices among clinicians.
- An online voting process involving Dutch dermatologists led to consensus on 15 recommendations for dose reduction eligibility, criteria for discontinuation, and specific dosing schedules for commonly used biologics.
- The final recommendations and an implementation algorithm are intended to help doctors make informed decisions about reducing biologic treatment in stable psoriasis patients, improving care consistency for their patients.
Background: When skin abnormalities in patients extend over several dermatomes, disseminated herpes zoster should be suspected. This complication is most often seen in immunocompromised patients.
Case Description: An 87-year-old patient came to the dermatology outpatient clinic with several vesicles scattered over her body.
Background: Sequential chemotherapy and individualised accelerated radiotherapy (INDAR) has been shown to be effective in non-small cell lung cancer (NSCLC), allowing delivering of high biological doses. We therefore performed a phase II trial (clinicaltrials.gov; NCT00572325) investigating the same strategy in concurrent chemo-radiation in stage III NSCLC.
View Article and Find Full Text PDFPurpose: We previously showed that individualized radiation dose escalation based on normal tissue constraints would allow safe administration of high radiation doses with low complication rate. Here, we report the mature results of a prospective, single-arm study that used this individualized tolerable dose approach.
Patients And Methods: In total, 166 patients with stage III or medically inoperable stage I to II non-small-cell lung cancer, WHO performance status 0 to 2, a forced expiratory volume at 1 second and diffusing capacity of lungs for carbon monoxide >or= 30% were included.